Phase 3 Trial Finds Longer Median Survival With Divarasib

Median overall survival was 17.7 months with divarasib and 12.0 months with sotorasib or adagrasib in patients with previously treated KRAS G12C-mutated lung cancer.
Read the full report on Econotimes
Story file
- Section
- Business
- Topics
- Health alerts
- First reported by
- Econotimes
- Reporter
- naomi calder
- Published
- Monday, 26 October 2026, 2:21 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Econotimes with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
